Search
Elutia Inc
ELUTAdd to Watchlist
0.932USD
-0.012-1.28%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
41.20MMarket Cap
0.77P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-1.28%
5 Days
-6.71%
1 Month
-11.24%
6 Months
+44.90%
Year to Date
+34.55%
1 Year
-55.41%
Key Figures
0.954Open
0.979High
17.56KVolume
0.77P/E TTM
LossP/E Dynamic
--Dividend TTM
0.04%Turnover Ratio
0.944Prev. Close
0.930Low
11.35KTurnover
LossP/E Static
1.83P/B
0.00%Div Yield TTM
-46.30%ROA
2.64052wk High
0.35Volume Ratio
-53.95MNet Profit
44.21MShares
1.2170EPS TTM
0.79Beta
-775.14%ROE
0.50052wk Low
5.19%Amplitude
57.87%Gross Margin
41.20MMarket Cap
-1.92Reward/Risk
5.26%Risk Rate
TradingKey Stock Score of Elutia Inc
Currency: USD Updated: 2026-07-02Key Insights
Elutia Inc's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 94 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 5.00.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Elutia Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Elutia Inc Highlights
StrengthsRisks
Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Women’s Health and Cardiovascular markets. In Women’s Health, it offers SimpliDerm, a novel biological matrix that leverages the inherent science of natural healing processes. SimpliDerm's design uses human-based hydrated acellular dermal matrix (ADM), which mitigates inflammation and enhances tissue incorporation. In Cardiovascular, it sells its specialized porcine small intestine submucosa for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population. It is focused on advancing NXT-41x, a biomatrix that directly addresses the root causes of reconstruction infections following mastectomy. NXT-41x combines biologics and extended antibiotic release to provide protection while supporting tissue regeneration.
Growing
The company is in a growing phase, with the latest annual income totaling USD 12.29M.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 0.77, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 21.86M shares, decreasing 21.24% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
5.000
Target Price
+429.60%
Upside Space
Elutia Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Elutia Inc Info
Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Women’s Health and Cardiovascular markets. In Women’s Health, it offers SimpliDerm, a novel biological matrix that leverages the inherent science of natural healing processes. SimpliDerm's design uses human-based hydrated acellular dermal matrix (ADM), which mitigates inflammation and enhances tissue incorporation. In Cardiovascular, it sells its specialized porcine small intestine submucosa for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population. It is focused on advancing NXT-41x, a biomatrix that directly addresses the root causes of reconstruction infections following mastectomy. NXT-41x combines biologics and extended antibiotic release to provide protection while supporting tissue regeneration.
Ticker SymbolELUT
CompanyElutia Inc
CEOMills (C. Randal)
Websitehttps://elutia.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Elutia Inc (ELUT)?
The current price of Elutia Inc (ELUT) is 0.93.
What is the symbol of Elutia Inc?
The ticker symbol of Elutia Inc is ELUT.
What is the 52-week high of Elutia Inc?
The 52-week high of Elutia Inc is 2.64.
What is the 52-week low of Elutia Inc?
The 52-week low of Elutia Inc is 0.50.
What is the market capitalization of Elutia Inc?
The market capitalization of Elutia Inc is 41.20M.
Is Elutia Inc (ELUT) currently rated as Buy, Hold, or Sell?
According to analysts, Elutia Inc (ELUT) has an overall rating of Buy, with a price target of 5.00.
What is the Earnings Per Share (EPS TTM) of Elutia Inc (ELUT)?
The Earnings Per Share (EPS TTM) of Elutia Inc (ELUT) is 1.29.